Catalent Pharma Solutions has completed the second phase of an expansion programme at its facility in Kansas City, Missouri.
The $5.5m expansion programme will allow the company to enhance the controlled-substance and controlled-temperature storage capabilities for its clinical supply business.
With the completion of the programme, the company has concluded a two-year project that has also expanded the facility’s highly-potent, cytotoxic and cold storage clinical drug packaging capabilities.
Catalent provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
The latest expansion, which includes a new Drug Enforcement Administration (DEA) Schedule I and II controlled substance vault, adds 3,600ft² of storage.
In addition, the facility will have additional controlled temperature storage capacity with 450 new pallet locations and 500 new high-density storage locations.
In order to ensure the security and integrity of samples in storage, the company has also added a new sampling room and an emergency generator.
Catalent Pharma Solutions Clinical Supply Services general manager Kevin Economos said: “Catalent customers have benefitted from our integrated analytical, oral solid manufacturing, and clinical supply services which our Kansas City campus has offered continuously for over 18 years.
“These latest expansions are critical enablers to our customers’ continued growth that reinforce our comprehensive global network, and enhance Catalent’s role as a market leader in the clinical supply industry.”
The services provided by the company at the 450,000ft² Kansas City facility include development and analytical support, as well as packaging and distribution.
Recently, Catalent announced new capabilities and capacity at two of its other clinical supply facilities in Philadelphia and Singapore.